Zürcher Nachrichten - Treatment improves cognition in Down Syndrome patients

EUR -
AED 4.02547
AFN 78.958383
ALL 99.102869
AMD 431.181955
ANG 1.961978
AOA 1003.890567
ARS 1184.765046
AUD 1.813586
AWG 1.97271
AZN 1.867466
BAM 1.955265
BBD 2.22659
BDT 133.983319
BGN 1.957778
BHD 0.412787
BIF 3277.602688
BMD 1.09595
BND 1.474296
BOB 7.619914
BRL 6.405394
BSD 1.102698
BTN 94.079244
BWP 15.358795
BYN 3.608812
BYR 21480.619234
BZD 2.215094
CAD 1.559263
CDF 3148.664634
CHF 0.944431
CLF 0.02729
CLP 1047.223301
CNY 7.980215
CNH 7.994999
COP 4582.945323
CRC 557.847278
CUC 1.09595
CUP 29.042674
CVE 110.234821
CZK 25.256829
DJF 196.376238
DKK 7.461451
DOP 69.640934
DZD 146.03502
EGP 55.406831
ERN 16.439249
ETB 145.347308
FJD 2.537019
FKP 0.847795
GBP 0.850992
GEL 3.01429
GGP 0.847795
GHS 16.970527
GIP 0.847795
GMD 78.997119
GNF 9480.074229
GTQ 8.45127
GYD 228.536272
HKD 8.520633
HNL 28.038338
HRK 7.531044
HTG 143.530764
HUF 404.54591
IDR 18346.949665
ILS 4.100568
IMP 0.847795
INR 93.650132
IQD 1430.891791
IRR 46360.405806
ISK 144.204462
JEP 0.847795
JMD 172.42419
JOD 0.777072
JPY 161.061946
KES 141.527433
KGS 95.002298
KHR 4365.330633
KMF 489.529208
KPW 986.361205
KRW 1599.015607
KWD 0.337157
KYD 0.910826
KZT 556.162432
LAK 23685.841231
LBP 98372.711411
LKR 324.07413
LRD 218.985421
LSL 20.902803
LTL 3.236056
LVL 0.66293
LYD 5.289988
MAD 10.429326
MDL 19.551233
MGA 5069.578931
MKD 61.05679
MMK 2300.919896
MNT 3846.361639
MOP 8.775473
MRU 43.593447
MUR 49.000806
MVR 16.923331
MWK 1897.317993
MXN 22.386696
MYR 4.861215
MZN 70.003894
NAD 20.902803
NGN 1681.066767
NIO 40.290501
NOK 11.790932
NPR 149.910449
NZD 1.95777
OMR 0.421946
PAB 1.09595
PEN 4.037053
PGK 4.46999
PHP 62.764717
PKR 306.904853
PLN 4.245513
PYG 8757.469729
QAR 3.989667
RON 4.952931
RSD 116.586887
RUB 93.840941
RWF 1555.449869
SAR 4.110221
SBD 9.312612
SCR 15.97682
SDG 658.021292
SEK 10.947921
SGD 1.470849
SHP 0.861245
SLE 24.933268
SLL 22981.523891
SOS 624.324825
SRD 40.248477
STD 22683.951476
SVC 9.589967
SYP 14249.994157
SZL 20.902803
THB 37.792726
TJS 11.899889
TMT 3.833642
TND 3.357047
TOP 2.638671
TRY 41.641737
TTD 7.422798
TWD 36.332658
TZS 2923.758392
UAH 45.158896
UGX 4009.400205
USD 1.09595
UYU 46.167964
UZS 14171.813622
VES 77.086835
VND 28252.54745
VUV 134.896075
WST 3.078778
XAF 652.705611
XAG 0.037037
XAU 0.000361
XCD 2.966325
XDR 0.817067
XOF 652.705611
XPF 119.331742
YER 269.409315
ZAR 20.929909
ZMK 9864.868719
ZMW 30.636217
ZWL 352.89544
  • RBGPF

    69.0200

    69.02

    +100%

  • RELX

    -3.2800

    48.16

    -6.81%

  • NGG

    -3.4600

    65.93

    -5.25%

  • GSK

    -2.4800

    36.53

    -6.79%

  • BTI

    -2.0600

    39.86

    -5.17%

  • RYCEF

    -1.5500

    8.25

    -18.79%

  • CMSC

    0.0300

    22.29

    +0.13%

  • VOD

    -0.8700

    8.5

    -10.24%

  • SCS

    -0.0600

    10.68

    -0.56%

  • CMSD

    0.1600

    22.83

    +0.7%

  • RIO

    -3.7600

    54.67

    -6.88%

  • JRI

    -0.8600

    11.96

    -7.19%

  • AZN

    -5.4600

    68.46

    -7.98%

  • BCC

    0.8100

    95.44

    +0.85%

  • BCE

    0.0500

    22.71

    +0.22%

  • BP

    -2.9600

    28.38

    -10.43%

Treatment improves cognition in Down Syndrome patients
Treatment improves cognition in Down Syndrome patients / Photo: Andreas SOLARO - AFP/File

Treatment improves cognition in Down Syndrome patients

A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.

Text size:

However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.

"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.

Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.

Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.

Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.

GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.

"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.

- Mice research -

The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.

They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.

The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.

A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.

They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.

Cognition and smell tests were carried out during the treatment, as were MRI scans.

Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.

"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.

The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.

- 'Improve quality of life' -

The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".

"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.

A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.

"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.

Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".

He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.

It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.

"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."

G.Kuhn--NZN